Explore the NIHProtocol Details
The Role of Autoimmunity in Neurologic Complications of Celiac Disease
This study is currently recruiting participants.
Summary | Eligibility | Citations | Contacts
Summary
Number |
08-N-0153 |
Sponsoring Institute |
National Institute of Neurological Disorders and Stroke (NINDS) |
Recruitment Detail |
Type: Participants currently recruited/enrolled |
Referral Letter Required |
No |
Population Exclusion(s) |
Children |
Special Instructions |
Currently Not Provided |
Keywords |
Celiac Disease; |
Recruitment Keyword(s) |
Celiac Disease; |
Condition(s) |
Ataxia |
Investigational Drug(s) |
None |
Investigational Device(s) |
None |
Intervention(s) |
None |
Supporting Site |
|
People 18 years of age and older with 1) ataxia and no celiac disease, 2) ataxia plus celiac disease and 3) matched healthy control subjects will be enrolled at the NIH. People with celiac disease only will be enrolled at Cornell University.
All participants have a blood sample drawn for various tests of immune function as well as genetic tests. Healthy volunteers also have a history and physical examination if they have not had one done at NIH in the past year. Some patients may require additional clinical evaluations for clinical or diagnostic reasons.
Eligibility
INCLUSION CRITERIA:
We plan to evaluate serum and blood from patients with gluten sensitivity (including both biopsy-proven CD, and biopsy-negative cases with high anti-gliadin antibody titer) accompanied by cerebellar ataxia. Serum samples will be acquired prior to initiation of a gluten-free diet. Therefore, several inclusion criteria exist based on the study group:
INCLUSION CRITERIA FOR PATIENTS WITH CD PLUS CEREBELLAR ATAXIA:
-The patient meets criteria for CD based on the modified ESPGAN criteria
-The patient has ataxia with or without neuropathy based on clinical evaluation
-The patient is free from other neurological and psychiatric deficits
-All other known causes for ataxia have been ruled out through routine clinical evaluations
-The patient is at least 18 years old and is willing to participate in the protocol
-The patient is not taking medications that are commonly known to have immune modulating effects.
-The patient is not on a gluten free diet
INCLUSION CRITERIA FOR PATIENTS WITH HEREDITARY CEREBELLAR ATAXIA WITHOUT CD:
-The patient tested negative for serologic markers of CD (i.e. antigliadin, antireticulin, and antiendomysial antibody testing as performed under protocol 93-N-0202)
-The patient has ataxia on routine clinical examination and no other neurological or psychiatric problems
-The patient has a known autosomal dominant ataxia (i.e., SCA, DRPLA, Friedreich's ataxia, and etc).
INCLUSION CRITERIA FOR MATCHED-CONTROLS:
-They should not have CD and or ataxia based on clinical evaluation and history
-Serologic testing for antigliadin, antireticulin, and antiendomysial antibodies should reveal negative results
-They should be race and age-matched with patients with CD and the ataxia group.
-They should have no neurological or psychiatric conditions based on clinical evaluation and history
-They should not have any rheumatological or autoimmune conditions in them or in their first degree relatives.
-They should be at least 18 years of age and be able to provide consent for participation
-They should not be on any immune modulating medications.
Final diagnosis of CD will strictly follow the modified criteria of the European Society for Pediatric Gastroenterology and Nutrition (ESPGAN) and recommendations of the recently held National Institutes of Health Consensus Development Conference on Celiac Disease. Assessment and diagnosis of cerebellar ataxia will be made by magnetic resonance imaging of the brain, clinical examination and genetic testing for spinocerebellar ataxias and Friedreich's ataxia. Additional routine testing will be done if necessary to exclude other causes.
Healthy and disease control groups will be evaluated for CD and for neurological deficits. Only symptom-free, antibody-negative individuals will be recruited into these control groups. Exclusion of neurological deficits and psychiatric illness in healthy and disease control subjects will be by history and neurological examination.
EXCLUSION CRITERIA:
For all groups, if other neurological and psychiatric diagnoses are present, the individual will not qualify to participate in this study.
EXCLUSION CRITERIA FOR ALL GROUPS:
-Subject is already on a gluten-restricted diet.
-Is taking known immune modulating therapy
-Have other neurological condition (except for neuropathy) or psychiatric condition
-Not willing to have blood drawn
-Is known to have immune dysfunction
-Being pregnant leads to numerous physiological changes. It is unclear if antibody characteristics are influenced by these changes.
Citations:
Contacts:
Principal Investigator |
Referral Contact |
For more information: |
| Mark Hallett, M.D. National Institute of Neurological Disorders and Stroke (NINDS) National Institutes of Health Building 10 Room 7D37 10 Center Drive Bethesda, Maryland 20892 (301) 496-9526 hallettm@ninds.nih.gov |
Elaine P. Considine, R.N. National Institute of Neurological Disorders and Stroke (NINDS) National Institutes of Health Building 10 Room 7D36 10 Center Drive Bethesda, Maryland 20892 (301) 435-8518 considinee@ninds.nih.gov |
Patient Recruitment and Public Liaison Office Building 61 10 Cloister Court Bethesda, Maryland 20892-4754 Toll Free: 1-800-411-1222 TTY: 301-594-9774 (local),1-866-411-1010 (toll free) Fax: 301-480-9793 prpl@mail.cc.nih.gov |
Clinical Trials Number:
NCT00692861
QUESTIONS?
Contact the Patient Recruitment and Public Liaison Office for:
- Details on how to participate in a study
- Details on how to refer a patient to a study
NIH Clinical Studies Information Request
Contact the Office of Communications for:
- General information about the NIH Clinical Center
Contact the Department Clinical Research Informatics, (DCRI) for:
- Technical questions about Adobe Acrobat and the PDF format
- Technical questions about this web server
